Hims & Hers Health Sees Unusually High Options Volume (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) was the target of unusually large options trading on Tuesday. Traders acquired 129,982 call options on the company. This is an increase of 29% compared to the average volume of 100,697 call options.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on HIMS. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their price target for the stock from $44.00 to $30.00 in a research note on Tuesday. Leerink Partners upped their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Morgan Stanley lowered their price target on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a report on Tuesday. Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Finally, Bank of America upped their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $36.92.

Hims & Hers Health Trading Up 7.2 %

Hims & Hers Health stock traded up $2.60 during mid-day trading on Friday, hitting $38.76. The stock had a trading volume of 10,713,431 shares, compared to its average volume of 16,596,686. The firm's 50 day moving average is $32.19 and its 200 day moving average is $31.30. Hims & Hers Health has a one year low of $11.20 and a one year high of $72.98. The firm has a market capitalization of $8.61 billion, a P/E ratio of 88.43 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. As a group, equities research analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 4,152 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now owns 157,345 shares of the company's stock, valued at $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the sale, the chief executive officer now directly owns 97,687 shares in the company, valued at $5,692,221.49. This trade represents a 56.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 666,234 shares of company stock valued at $26,387,645. 17.71% of the stock is owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Large investors have recently bought and sold shares of the business. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at $28,000. Raleigh Capital Management Inc. grew its stake in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares during the period. Blume Capital Management Inc. lifted its stake in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares in the last quarter. UMB Bank n.a. raised its holdings in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after acquiring an additional 933 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.